ValuEngine upgraded shares of Medicure Inc. (OTCMKTS:MCUJF) from a buy rating to a strong-buy rating in a research report released on Saturday morning.

Medicure (OTCMKTS:MCUJF) traded up 11.82% during trading on Friday, reaching $6.15. 1,300 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $5.35 and its 200-day moving average price is $6.60. The stock has a market cap of $95.73 million, a P/E ratio of 6.49 and a beta of 0.52. Medicure has a one year low of $4.11 and a one year high of $7.96.

COPYRIGHT VIOLATION WARNING: “Medicure Inc. (MCUJF) Upgraded by ValuEngine to “Strong-Buy”” was published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.financial-market-news.com/2017/06/17/medicure-inc-mcujf-upgraded-by-valuengine-to-strong-buy.html.

Medicure Company Profile

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.